Our results, showing that Wnt1 transactivates EGFR in tumor cell lines, imply that, in breast cancer, constitutive WNT signaling might impact not only on the canonical pathway, but also on EGFR activity by stimulating ligand availability. The gene discussed is EGFR; the disease is neoplasm.